Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 13,975 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined treatment Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
View directory record Official record
Conditions
C-Section, Pain Management
Interventions
Exparel + Bupivacaine, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

NCT04640779
View directory record Official record
Conditions
Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma
Interventions
Choline Salicylate, Selinexor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 25, 2026, 3:02 PM EDT
Not listed Phase 1Phase 2 Interventional

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

NCT05266196
View directory record Official record
Conditions
Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
Interventions
Seclidemstat
Drug
Lead sponsor
Salarius Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 3:02 PM EDT
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1 Interventional Results available

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

NCT05177042
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Bavdegalutamide, Abiraterone
Drug
Lead sponsor
Arvinas Androgen Receptor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

NCT00075270
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Paclitaxel, GW572016 (Lapatinib)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
45
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Benzodiazepine Discontinuation in Opioid Agonist Therapy

NCT04109118
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), BZD discontinuation protocol
Behavioral · Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

NCT02659020
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Gemcitabine, Docetaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
16 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
21
States / cities
Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

NCT02311582
View directory record Official record
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments

NCT02551562
View directory record Official record
Conditions
Subjects Requesting and Requiring Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
Interventions
NuDerm® System, Placebo
Other
Lead sponsor
DeNova Research
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

NCT00005946
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 25, 2026, 3:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Cell Therapy for Knee Cartilage Repair

NCT04001361
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Laser Cell Therapy
Procedure
Lead sponsor
Endocellutions
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Steubenville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 25, 2026, 3:02 PM EDT
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 3:02 PM EDT
Recruiting Phase 3 Interventional

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Interventions
Cantharidin
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Saint Augustine, Florida • Plainfield, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Drug and Talk Therapy for Fibromyalgia

NCT01038323
View directory record Official record
Conditions
Fibromyalgia
Interventions
CBT and milnacipran, CBT with a placebo, Educational with milnacipran
Other · Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

NCT00743379
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Bladder and Sexual Function After Spinal Cord Injury

NCT03036527
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Activity-based locomotor training, Activity-based stand training, Activity-based upper arm ergometry, Activity-based training + spinal epidural stimulation
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 25, 2026, 3:02 PM EDT
Terminated Phase 1 Interventional

BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00028561
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, carboplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 25, 2026, 3:02 PM EDT
Completed No phase listed Observational

Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems

NCT00001097
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 22 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

NCT00715520
View directory record Official record
Conditions
Stroke
Interventions
Transcranial Magnetic Stimulation (TMS), Carbidopa-Levodopa, Methylphenidate, Amphetamine Sulfate, Placebo, Sham Transcranial Magnetic Stimulation (TMS), Transcranial Magnetic Stimulation (TMS) Training
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 25, 2026, 3:02 PM EDT
Terminated Not applicable Interventional

Evaluating Wound Healing With Next Science Gel & Wash.

NCT03738579
View directory record Official record
Conditions
Chronic Wound
Interventions
Next Science Group, Control Group, Antibacterial Control Group
Device
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 25, 2026, 3:02 PM EDT
Completed Phase 4 Interventional

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

NCT00358124
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin glargine, rosiglitazone, metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 25, 2026, 3:02 PM EDT